Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control a...
Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes
About this item
Full title
Author / Creator
Publisher
Alexandria, VA: American Diabetes Association
Journal title
Language
English
Formats
Publication information
Publisher
Alexandria, VA: American Diabetes Association
Subjects
More information
Scope and Contents
Contents
OBJECTIVE:--In patients with type 2 diabetes, exenatide reduces A1C, postprandial and fasting glucose, and weight. In this study we investigated the effects of continuous exenatide administration from a long-acting release (LAR) formulation. RESEARCH DESIGN AND METHODS--In this randomized, placebo-controlled phase 2 study, exenatide LAR (0.8 or 2.0...
Alternative Titles
Full title
Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_crossref_citationtrail_10_2337_dc06_2375
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_crossref_citationtrail_10_2337_dc06_2375
Other Identifiers
ISSN
0149-5992
E-ISSN
1935-5548
DOI
10.2337/dc06-2375
